Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 773 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cardiovascular Disease Prevention Clear all
Completed Not applicable Interventional

Behavior Change Family Counseling to Reduce Rate of Weight Gain in At-Risk Children

NCT00241891
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Obesity
Interventions
Single behavior intervention, Multiple behavior interventions, Control Intervention unrelated to weight
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 12 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Not applicable Interventional Results available

Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology

NCT01696760
View directory record Official record
Conditions
Bone Metastases, Musculoskeletal Cancer, Soft Tissue Sarcoma, Thromboembolism
Interventions
acetylsalicylic acid, enoxaparin, PCD
Drug · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 15, 2026, 5:27 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Home-Based Measures of Physical Activity and Body Composition

NCT00542438
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Physical Activity Recall, Environmental Assessments
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

NCT02741596
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Not applicable Interventional Results available

Virtual Lifestyle Management: Prevention Through the UPMC Patient Portal

NCT00409786
View directory record Official record
Conditions
Obesity
Interventions
Virtual Lifestyle Management (VLM)
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2011 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

NCT00097786
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo, Valsartan placebo + nateglinide placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 99 Years
Enrollment
9,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Multiple Locations, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 15, 2026, 5:27 PM EDT
Recruiting No phase listed Observational

Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention

NCT00733590
View directory record Official record
Conditions
Heart Failure, Congestive, Death, Sudden, Cardiac, Arrhythmia, Cardiomyopathies
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2029
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT

NCT00585182
View directory record Official record
Conditions
Obesity, Venous Thrombosis, Anticoagulants
Interventions
Enoxaparin 0.5 mg/kg once daily
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 15, 2026, 5:27 PM EDT
Not listed No phase listed Observational

Evaluation of Chemical Venous Thromboembolism Prophylaxis in Trauma

NCT06025162
View directory record Official record
Conditions
Thromboembolism, Venous
Interventions
enoxaparin
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 120 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 15, 2026, 5:27 PM EDT
Active, not recruiting Not applicable Interventional

GaitBetter: Motor and Cognitive Training for Gait Rehabilitation and Falls Prevention in Stroke Survivors.

NCT04625127
View directory record Official record
Conditions
Stroke, Gait, Hemiplegic, Hemiplegia
Interventions
Treadmill gait training with GaitBetter, Treadmill gait training with GaitBetter + Standard of care, Standard of care
Device · Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 15, 2026, 5:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

Polypill for Prevention of Cardiomyopathy

NCT06143566
View directory record Official record
Conditions
Type 2 Diabetes, High Blood Pressure
Interventions
Polypill, Combined prescription of the individual medications
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Not applicable Interventional

Decreasing Cardiovascular Risk for Patients With Diabetes

NCT04874116
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Office Guidelines Applied to Practice (Office-GAP) + Mobile text messaging, Mobile text messaging
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.

NCT00362232
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin, Placebo: tablet of Rivaroxaban, Placebo: syringes of Enoxaparin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Phase 2 Interventional

Multicenter Trial of Meditation and Health Education for Cardiometabolic Disease in Black Women

NCT06443814
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Metabolic Syndrome
Interventions
Health Education, Transcendental Meditation
Behavioral
Lead sponsor
Robert Schneider, MD
Other
Eligibility
55 Years and older · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Minority Health Through Biofeedback and Stress Reduction

NCT07172152
View directory record Official record
Conditions
Cardiovascular Disease Risk Reduction, Chronic Stress, Anxiety, Emotional Regulation, Hypertension Prevention, Health Disparities
Interventions
HRV Biofeedback Training
Behavioral
Lead sponsor
Amelia Saul, PhD, CTRS, BCB
Other
Eligibility
18 Years to 35 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 15, 2026, 5:27 PM EDT
Not yet recruiting Phase 2 Interventional

SAMe in Prevention of Oxaliplatin-associated Liver Injury

NCT06258525
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Liver Injury, Sinusoidal Obstruction Syndrome, 5-Fluorouracil Toxicity, Liver Toxicity, Chemically-Induced
Interventions
Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery
Radiation · Dietary Supplement · Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Not applicable Interventional Results available

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

NCT00293384
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Lifestyle Physical Activity Intervention for Older Sedentary Women

NCT01707693
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Lifestyle Physical Activity Intervention, Information / Attention Comparison
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
60 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2019 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study Comparing Desirudin With Heparin to Prevent Vein Clots After Heart and Lung Surgery

NCT00329433
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Desirudin (Iprivask™), Heparin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

NCT01991795
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Ticagrelor 60 mg, Ticagrelor placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
19,271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
295
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 238 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 15, 2026, 5:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US

NCT05129345
View directory record Official record
Conditions
Hypertension, Dyslipidemias, Type 2 Diabetes, HIV-1-infection
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Charlotte, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 15, 2026, 5:27 PM EDT
Not listed Phase 4 Interventional

Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension

NCT04908982
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
Aspirin 81mg
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

NCT02586805
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 15, 2026, 5:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

NCT00520130
View directory record Official record
Conditions
Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia, Multiple Myeloma
Interventions
Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT), Conditioning Chemotherapy, TMS, FLAG, EPOCH-F, Alemtuzumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 74 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 15, 2026, 5:27 PM EDT